Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins
View Patent ↗The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
1. An isolated nucleic acid comprising SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, which isolated nucleic acid encodes a chain of a protein that binds to CD40.
2. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, said chain comprising SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, which protein binds to CD40.
3. The isolated nucleic acid of claim 2 comprising a nucleotide sequence encoding a protein chain comprising (a) a heavy chain variable domain of monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and (b) a human constant region.
4. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, said chain comprising an amino acid sequence that has at least 95% identity to SEQ ID NO:7 over the full length of SEQ ID NO:7, which protein competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110.
5. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody heavy chain, which antibody competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and which antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.
6. An isolated nucleic acid comprising a nucleotide sequence encoding a fusion protein, said fusion protein comprising an amino acid sequence of bryodin 1 (BD1) fused to SEQ ID NO:7 fused to SEQ ID NO:2.
7. An isolated nucleic acid which hybridizes to the complement of a DNA consisting of a coding DNA sequence encoding a protein consisting of the amino acid sequence of SEQ ID NO:7, under highly stringent conditions, which isolated nucleic acid encodes a chain of a protein that competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and wherein said highly stringent conditions are achieved by a method comprising the steps of:
(a) prehybridizing filters containing said complement for 8 hours to overnight at 65° C. in buffer composed of 6×SSC, 50 mM Tris HCl (pH 7.5). 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA;
(b) hybridizing the filters of step (a) for 48 h at 65° C. in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20×10 6 cpm of 32 P -labeled probe;
(c) washing the filters of step (b) at 37° C. for 1 hour in a solution containing 2×SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA; and
(d) washing the filters of step (c) in 0.1×SSC at 50° C. for 45 min.
8. An in vitro recombinant cell, said cell containing a recombinant nucleic acid comprising a nucleotide sequence encoding an antibody heavy chain, which heavy chain comprises a human constant domain, and which antibody competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and which antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.
9. An in vitro recombinant cell, said cell containing a recombinant nucleic acid encoding a protein, said protein comprising SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15 and further comprising a human constant domain.
10. A method of producing an antibody heavy chain, comprising:
(a) growing a cell in culture, said cell containing a recombinant nucleic acid encoding an antibody heavy chain, which heavy chain comprises a, human constant domain, and which antibody competes for binding to CD40 with monoclonal antibody S2C6 as deposited with the ATCC and assigned accession number PTA-110, and which antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, such that the antibody heavy chain is expressed by the cell; and
(b) recovering the expressed antibody heavy chain.
11. A method of producing a protein comprising:
(a) growing a cell in culture, said cell containing a recombinant nucleic acid encoding a protein comprising SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 and a human constant domain, such that said protein is expressed by the cell; and
(b) recovering the expressed protein.
12. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, wherein said chain comprises SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 and is a fusion protein comprising the amino acid sequence of a second protein that is not an antibody, and wherein said protein binds CD40.
13. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, said chain comprising an amino acid sequence that has at least 95% identity to SEQ ID NO:7 over the full length of SEQ ID NO:7, which protein (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110; and (b) comprises a human immunoglobulin constant domain.
14. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, said chain comprising an amino acid sequence that comprises regions having at least 80% identity to SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, over the full length of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, which protein (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110; and (b) comprises a human immunoglobulin constant domain.
15. The isolated nucleic acid of claim 14 , wherein the chain comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10.
16. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody heavy chain, which antibody (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110; (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%; and (c) comprises a human immunoglobulin constant domain.
17. An isolated nucleic acid comprising a nucleotide sequence encoding a chain of a protein, which protein competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110 and comprises a human immunoglobulin constant domain, and which chain comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10.
18. The isolated nucleic acid of claim 17 , wherein the chain comprises SEQ ID NO:8 and SEQ ID NO:10.
19. The isolated nucleic acid of any of claims 13 - 15 , 17 and 18 , wherein the protein is an antibody.
20. The isolated nucleic acid of claim 19 , wherein the antibody is a chimeric antibody.
21. The isolated nucleic acid of claim 19 , wherein the antibody is a humanized antibody.
22. The isolated nucleic acid of claim 12 , wherein the chain comprises SEQ ID NO:7.
23. The isolated nucleic acid of claim 12 or 22 , wherein the chain further comprises SEQ ID NO:2.
24. The isolated nucleic acid of claim 5 or 16 , wherein the antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.
25. The isolated nucleic acid of claim 5 or 16 , wherein the antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.
26. The isolated nucleic acid of claim 5 or 16 , wherein the antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.
27. The isolated nucleic acid of claim 1 , 2 , 4 , 7 , 12 , 13 , 14 or 17 , wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.
28. The isolated nucleic acid of claim 1 , 2 , 4 , 7 , 12 , 13 , 14 or 17 , wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.
29. The isolated nucleic acid of claim 1 , 2 , 4 , 7 , 12 , 13 , 14 or 17 , wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.
30. The isolated nucleic acid of claim 1 , 2 , 4 , 7 , 12 , 13 , 14 or 17 , wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.
31. The isolated nucleic acid of claim 1 which comprises SEQ ID NO:6.
32. The isolated nucleic acid of claim 2 , wherein the chain comprises SEQ ID NO:7.
33. The recombinant cell of claim 9 , wherein the recombinant nucleic acid comprises SEQ ID NO:6.
34. The method of claim 11 , wherein the recombinant nucleic acid encodes SEQ ID NO:7.
35. The nucleic acid of claim 12 , wherein the second protein is a toxin or enzyme.